Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
Philip ZeitlerRodolfo J GalindoMelanie J DaviesBrandon K BergmanVivian T ThieuClaudia NicolaySheryl AllenRobert J HeineA Richey SharrettPublished in: Diabetes care (2024)
Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.
Keyphrases
- early onset
- type diabetes
- late onset
- clinical trial
- quality improvement
- glycemic control
- healthcare
- public health
- mental health
- cardiovascular disease
- insulin resistance
- study protocol
- randomized controlled trial
- current status
- metabolic syndrome
- combination therapy
- replacement therapy
- double blind
- human health
- adipose tissue
- climate change